JP6692836B2 - Ｊａｋキナーゼ阻害剤としてのナフチリジン化合物 - Google Patents

Ｊａｋキナーゼ阻害剤としてのナフチリジン化合物 Download PDF

Info

Publication number
JP6692836B2
JP6692836B2 JP2017561259A JP2017561259A JP6692836B2 JP 6692836 B2 JP6692836 B2 JP 6692836B2 JP 2017561259 A JP2017561259 A JP 2017561259A JP 2017561259 A JP2017561259 A JP 2017561259A JP 6692836 B2 JP6692836 B2 JP 6692836B2
Authority
JP
Japan
Prior art keywords
alkyl
optionally substituted
amino
methyl
azabicyclo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017561259A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018515581A5 (enExample
JP2018515581A (ja
Inventor
ライアン ハドソン，
ライアン ハドソン，
ジェニファー コザック，
ジェニファー コザック，
ポール アール． ファザリー，
ポール アール． ファザリー，
ダンテ ディー． ポデスト，
ダンテ ディー． ポデスト，
ゲイリー イー．エル． ブラント，
ゲイリー イー．エル． ブラント，
メリッサ フルーリー，
メリッサ フルーリー，
アン−マリー ボーソレイユ，
アン−マリー ボーソレイユ，
シャオジュン ファン，
シャオジュン ファン，
ヴァンキャット アール． サラディー，
ヴァンキャット アール． サラディー，
Original Assignee
セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー
セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー, セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー filed Critical セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー
Publication of JP2018515581A publication Critical patent/JP2018515581A/ja
Publication of JP2018515581A5 publication Critical patent/JP2018515581A5/ja
Application granted granted Critical
Publication of JP6692836B2 publication Critical patent/JP6692836B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2017561259A 2015-05-28 2016-05-26 Ｊａｋキナーゼ阻害剤としてのナフチリジン化合物 Active JP6692836B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562167694P 2015-05-28 2015-05-28
US62/167,694 2015-05-28
US201662312273P 2016-03-23 2016-03-23
US62/312,273 2016-03-23
PCT/US2016/034243 WO2016191524A1 (en) 2015-05-28 2016-05-26 Naphthyridine compounds as jak kinase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020049467A Division JP6850922B2 (ja) 2015-05-28 2020-03-19 Ｊａｋキナーゼ阻害剤としてのナフチリジン化合物

Publications (3)

Publication Number Publication Date
JP2018515581A JP2018515581A (ja) 2018-06-14
JP2018515581A5 JP2018515581A5 (enExample) 2019-05-09
JP6692836B2 true JP6692836B2 (ja) 2020-05-13

Family

ID=56118022

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017561259A Active JP6692836B2 (ja) 2015-05-28 2016-05-26 Ｊａｋキナーゼ阻害剤としてのナフチリジン化合物
JP2020049467A Active JP6850922B2 (ja) 2015-05-28 2020-03-19 Ｊａｋキナーゼ阻害剤としてのナフチリジン化合物
JP2020155460A Active JP6942853B2 (ja) 2015-05-28 2020-09-16 Ｊａｋキナーゼ阻害剤としてのナフチリジン化合物
JP2021047526A Withdrawn JP2021098757A (ja) 2015-05-28 2021-03-22 Ｊａｋキナーゼ阻害剤としてのナフチリジン化合物

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2020049467A Active JP6850922B2 (ja) 2015-05-28 2020-03-19 Ｊａｋキナーゼ阻害剤としてのナフチリジン化合物
JP2020155460A Active JP6942853B2 (ja) 2015-05-28 2020-09-16 Ｊａｋキナーゼ阻害剤としてのナフチリジン化合物
JP2021047526A Withdrawn JP2021098757A (ja) 2015-05-28 2021-03-22 Ｊａｋキナーゼ阻害剤としてのナフチリジン化合物

Country Status (31)

Country Link
US (6) US9725470B2 (enExample)
EP (2) EP3303348B1 (enExample)
JP (4) JP6692836B2 (enExample)
KR (1) KR20180011272A (enExample)
CN (2) CN107667108B (enExample)
AU (2) AU2016267141B2 (enExample)
BR (1) BR112017025542A2 (enExample)
CA (1) CA2983453A1 (enExample)
CL (1) CL2017002994A1 (enExample)
CO (1) CO2017012267A2 (enExample)
CY (1) CY1122279T1 (enExample)
DK (1) DK3303348T3 (enExample)
EA (1) EA032953B1 (enExample)
ES (2) ES2924698T3 (enExample)
HU (1) HUE046130T2 (enExample)
IL (3) IL255358B (enExample)
LT (1) LT3303348T (enExample)
ME (1) ME03610B (enExample)
MX (2) MX378963B (enExample)
PH (1) PH12017502050B1 (enExample)
PL (1) PL3303348T3 (enExample)
PT (1) PT3303348T (enExample)
RS (1) RS59522B1 (enExample)
SA (1) SA517390337B1 (enExample)
SG (1) SG10201910742VA (enExample)
SI (1) SI3303348T1 (enExample)
SM (1) SMT201900587T1 (enExample)
TW (2) TWI746178B (enExample)
UA (1) UA121138C2 (enExample)
WO (1) WO2016191524A1 (enExample)
ZA (1) ZA201707326B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3303348B1 (en) 2015-05-28 2019-08-07 Theravance Biopharma R&D IP, LLC Naphthyridine compounds as jak kinase inhibitors
ES2840650T3 (es) 2015-11-03 2021-07-07 Topivert Pharma Ltd Derivados de 4,5,6,7-tetrahidro-1h-imidazo[4,5-c]piridina y 1,4,5,6,7,8-hexahidroimidazo[4,5-d]azepina como inhibidores de la quinasa janus
WO2017077283A1 (en) 2015-11-03 2017-05-11 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
CA3020506A1 (en) 2016-04-28 2017-11-02 Theravance Biopharma R&D Ip, Llc Pyrimidine compounds as jak kinase inhibitors
RS63500B1 (sr) 2016-12-16 2022-09-30 Janssen Pharmaceutica Nv Jedinjenja imidazo[4,5-d]pirolo[2,3-b]piridina kao inhibitori janus kinaza
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
SMT202200409T1 (it) 2017-10-27 2022-11-18 Theravance Biopharma R&D Ip Llc Composto di pirimidina come inibitore di chinasi jak
TW202016110A (zh) 2018-06-15 2020-05-01 比利時商健生藥品公司 Ｊａｋ激酶家族之小分子抑制劑
US12171764B2 (en) 2018-06-20 2024-12-24 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a JAK or other kinase inhibitor
TWI740288B (zh) * 2018-11-27 2021-09-21 大陸商江蘇豪森藥業集團有限公司 含氮雜芳類衍生物調節劑、其製備方法和應用
CA3121408A1 (en) * 2018-11-30 2020-06-04 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Heteroaromatic derivatives for use as regulator, preparation method therefor and use thereof
BR112021018168B1 (pt) 2019-03-21 2023-11-28 Onxeo Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer
TW202106681A (zh) 2019-04-24 2021-02-16 美商施萬生物製藥研發Ｉｐ有限責任公司 用於治療皮膚疾病之嘧啶jak抑制劑
WO2020219639A1 (en) 2019-04-24 2020-10-29 Theravance Biopharma R&D Ip, Llc Ester and carbonate pyrimidine compounds as jak kinase inhibitors
US20220401436A1 (en) 2019-11-08 2022-12-22 INSERM (Institute National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN113717202B (zh) * 2020-05-25 2025-10-17 上海翰森生物医药科技有限公司 杂芳类衍生物的自由碱晶型及其制备方法
CN115667228A (zh) * 2020-05-25 2023-01-31 上海翰森生物医药科技有限公司 杂芳类衍生物的盐、晶型及其制备方法
WO2022076709A1 (en) 2020-10-09 2022-04-14 Janssen Biotech, Inc. Formulation of a pan-jak inhibitor
WO2022076714A1 (en) * 2020-10-09 2022-04-14 Janssen Biotech, Inc. Solid forms of a pan-jak inhibitor
WO2022076717A1 (en) * 2020-10-09 2022-04-14 Janssen Biotech, Inc. Solvate forms of a pan-jak inhibitor
CN116368134A (zh) * 2020-10-09 2023-06-30 施万生物制药研发Ip有限责任公司 制备泛jak抑制剂的方法和相关中间体化合物
WO2022165529A1 (en) * 2021-02-01 2022-08-04 Janssen Biotech, Inc. Small molecule inhibitors of salt inducible kinases
KR20230156752A (ko) 2021-03-11 2023-11-14 얀센 파마슈티카 엔브이 Jak 매개 장애의 치료에 사용하기 위한 로르푸시티닙
WO2022241188A1 (en) 2021-05-14 2022-11-17 Theravance Biopharma R&D Ip, Llc Enantioselective synthesis of aminotropane compound
WO2023011359A1 (zh) * 2021-08-05 2023-02-09 南京明德新药研发有限公司 桥环类化合物及其应用
WO2023102800A1 (en) 2021-12-09 2023-06-15 Theravance Biopharma R&D Ip, Llc Synthesis of 5, 7-dichloro-1, 6-naphthyridine
WO2023202706A1 (zh) * 2022-04-21 2023-10-26 南京明德新药研发有限公司 硒杂环类化合物的盐型和晶型及其应用
KR20250042155A (ko) 2022-07-27 2025-03-26 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 축합 고리계 화합물, 이의 제조 방법 및 이의 의학적 응용
AU2024282654A1 (en) 2023-05-30 2025-12-04 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6613776B2 (en) 2000-09-15 2003-09-02 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
NZ526468A (en) 2000-12-21 2004-03-26 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors
EP1595881A1 (en) * 2004-05-12 2005-11-16 Pfizer Limited Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands
JP2008525422A (ja) * 2004-12-23 2008-07-17 ファイザー・プロダクツ・インク 抗癌剤として有用な複素芳香族誘導体
US7572809B2 (en) * 2005-12-19 2009-08-11 Hoffmann-La Roche Inc. Isoquinoline aminopyrazole derivatives
JP2010523522A (ja) * 2007-04-02 2010-07-15 パラウ・フアルマ・ソシエダツド・アノニマ Ｊａｋ３阻害剤としてのピロロピリミジン誘導体
WO2010002472A1 (en) * 2008-07-02 2010-01-07 Ambit Biosciences Corporation Jak kinase modulating compounds and methods of use thereof
US20110201608A1 (en) 2008-08-05 2011-08-18 Boehringer Ingelheim International Gmbh Substituted naphthyridines and use thereof as medicines
CA2737217A1 (en) 2008-09-30 2010-04-08 Astrazeneca Ab Heterocyclic jak kinase inhibitors
GB201007203D0 (en) 2010-04-29 2010-06-16 Glaxo Group Ltd Novel compounds
WO2012022045A1 (en) * 2010-08-20 2012-02-23 Hutchison Medipharma Limited Pyrrolopyrimidine compounds and uses thereof
EP2527344A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
CN105367555B (zh) 2014-08-07 2019-06-25 广东东阳光药业有限公司 取代的杂芳基化合物及其组合物和用途
EP3303348B1 (en) 2015-05-28 2019-08-07 Theravance Biopharma R&D IP, LLC Naphthyridine compounds as jak kinase inhibitors
CA3020506A1 (en) 2016-04-28 2017-11-02 Theravance Biopharma R&D Ip, Llc Pyrimidine compounds as jak kinase inhibitors

Also Published As

Publication number Publication date
IL272057B (en) 2020-09-30
WO2016191524A1 (en) 2016-12-01
US20160347772A1 (en) 2016-12-01
IL255358A0 (en) 2017-12-31
UA121138C2 (uk) 2020-04-10
ZA201707326B (en) 2018-11-28
US20200040010A1 (en) 2020-02-06
JP2021098757A (ja) 2021-07-01
ME03610B (me) 2020-07-20
PH12017502050A1 (en) 2018-04-23
IL276677A (en) 2020-09-30
BR112017025542A2 (pt) 2018-08-07
EP3569604B1 (en) 2022-07-06
PH12017502050B1 (en) 2018-04-23
CY1122279T1 (el) 2020-10-14
ES2924698T3 (es) 2022-10-10
LT3303348T (lt) 2019-11-25
CL2017002994A1 (es) 2018-03-09
MX2020011774A (es) 2021-06-01
EP3569604A1 (en) 2019-11-20
ES2753159T3 (es) 2020-04-07
EP3303348B1 (en) 2019-08-07
US10072026B2 (en) 2018-09-11
MX2017015211A (es) 2018-04-13
US10494382B2 (en) 2019-12-03
SI3303348T1 (sl) 2019-12-31
JP2020111593A (ja) 2020-07-27
AU2020202181B2 (en) 2021-07-01
IL272057A (en) 2020-02-27
SA517390337B1 (ar) 2021-03-31
JP2021001196A (ja) 2021-01-07
IL276677B (en) 2021-05-31
AU2016267141B2 (en) 2020-04-16
US20210179637A1 (en) 2021-06-17
HUE046130T2 (hu) 2020-02-28
EA032953B1 (ru) 2019-08-30
DK3303348T3 (da) 2019-11-11
US20170305934A1 (en) 2017-10-26
SG10201910742VA (en) 2020-01-30
HK1245771A1 (en) 2018-08-31
SMT201900587T1 (it) 2019-11-13
TW202108593A (zh) 2021-03-01
CO2017012267A2 (es) 2018-03-28
JP6850922B2 (ja) 2021-03-31
AU2016267141A1 (en) 2017-11-16
TWI704152B (zh) 2020-09-11
CN111362975B (zh) 2022-04-05
CN111362975A (zh) 2020-07-03
US12358931B2 (en) 2025-07-15
PL3303348T3 (pl) 2020-02-28
PT3303348T (pt) 2019-11-15
US10947254B2 (en) 2021-03-16
CN107667108B (zh) 2020-05-12
TW201716416A (zh) 2017-05-16
US20180354974A1 (en) 2018-12-13
IL255358B (en) 2020-01-30
US20240132520A1 (en) 2024-04-25
RS59522B1 (sr) 2019-12-31
AU2020202181A1 (en) 2020-04-16
US11780852B2 (en) 2023-10-10
KR20180011272A (ko) 2018-01-31
CA2983453A1 (en) 2016-12-01
JP2018515581A (ja) 2018-06-14
EA201792619A1 (ru) 2018-04-30
JP6942853B2 (ja) 2021-09-29
MX383074B (es) 2025-03-13
CN107667108A (zh) 2018-02-06
US9725470B2 (en) 2017-08-08
TWI746178B (zh) 2021-11-11
MX378963B (es) 2025-03-10
EP3303348A1 (en) 2018-04-11

Similar Documents

Publication Publication Date Title
JP6942853B2 (ja) Ｊａｋキナーゼ阻害剤としてのナフチリジン化合物
JP6881879B2 (ja) Ｊａｋキナーゼ阻害剤としてのピリミジン化合物
EP3652169A1 (en) Pyrazolo and triazolo bicyclic compounds as jak kinase inhibitors
HK40014855A (en) Process and intermediates for the preparation of naphthyridine compounds as jak kinase inhibitors
HK1245771B (en) Naphthyridine compounds as jak kinase inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190325

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190325

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191220

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20191226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200319

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200402

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200415

R150 Certificate of patent or registration of utility model

Ref document number: 6692836

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250